

Election of the chairman of the Meeting (item 2)

The Nomination Committee of Swedish Orphan Biovitrum AB (publ), which consists of Petra Hedengran, chairman (Investor AB), Håkan Björklund (chairman of the Board of Directors), Thomas Ehlin (The Fourth Swedish National Pension Fund (AP4)) and Lennart Francke (Swedbank Robur Fonder AB), proposes that attorney-at-law Eva Hägg from Mannheimer Swartling Advokatbyrå is elected chairman of the Meeting.

Fees for the members of the Board of Directors and the auditor (item 13)

The Nomination Committee proposes the following:

- that fees to be paid to the Board of Directors should be SEK 1,725,000 (1,675,000) to the chairman of the Board of Directors and SEK 570,000 (550,000) to each of the other members of the Board of Directors elected by the Annual General Meeting, that fees for work in the Audit Committee should be SEK 190,000 (185,000) to the chairman and SEK 110,000 (unchanged) to each other member of such committee, that fees for work in the Compensation & Benefits Committee should be SEK 125,000 (120,000) to the chairman and SEK 80,000 (70,000) to each other member of such committee and that fees for work in the Science Committee should be SEK 125,000 (120,000) to the chairman and SEK 80,000 (70,000) to each other member of such committee, that fees for work in another committee in accordance with a decision by the Board of Directors should be SEK 80,000 to each member of that committee,
- that, in addition to the fees proposed above, for each physical meeting of the Board of Directors held in Sweden, a meeting fee of SEK 20,000 (unchanged) is paid to the members of the Board of Directors that reside in Europe outside the Nordic countries and a meeting fee of USD 3,500 (unchanged) is paid to the members of the Board of Directors that reside outside Europe, and
- that the fees to the auditor should be paid in accordance with normal standards and approved invoice.

The number of members of the Board of Directors, deputy directors, auditors and deputy auditors (item 14)

The Nomination Committee proposes the following:

- that seven ordinary members of the Board of Directors without deputies should be appointed, and
- that one auditor without any deputy auditor should be appointed.

Election of the chairman, the members of the Board of Directors and the auditor (item 15)

The Nomination Committee proposes the following:

- that Annette Clancy, Bo Jesper Hansen, Helena Saxon, Staffan Schüberg and Filippa Stenberg should be re-elected as ordinary members of the Board of Directors, that Christophe Bourdon and Anders Ullman should be elected as new ordinary members of the Board of Directors and that Bo Jesper Hansen should be elected as new chairman of the Board of Directors, and
- that Ernst & Young AB should be re-elected as auditor of the company until the end of the Annual General Meeting 2024, in accordance with the Audit Committee's recommendation.

Christophe Bourdon

Christophe Bourdon (born 1970) holds an MBA from International Institute for Management (IMD) Business School, Switzerland, and a BA from ISG Business School, France.

Christophe is CEO of Leo Pharma A/S. His previous experience includes CEO of Orphazyme A/S, Senior Vice President, General Manager, U.S Oncology Business and member of the Operating Team at Amgen Inc. and Senior Vice President of Europe, Middle East, Africa and Canada at Alexion, as well as other key roles within the international pharmaceutical industry.

Anders Ullman

Anders Ullman (born 1956) holds an MD and PhD in Clinical Pharmacology from the University of Gothenburg, Sweden.

Anders is a board member of Verona Pharma plc.

Anders was Head of Research & Development and Medical Affairs and Chief Medical Officer at Sobi from January 2022 until 31 March 2023. For transitional purposes, Anders remains employed by Sobi until summer 2023, but not as a member of the executive committee. Prior to his employment with Sobi, Anders was a board member of Sobi from May 2021 to December 2021. He was previously a board member of NeuroSearch and of PExA. He was also the head of the COPD Centre at Sahlgrenska University Hospital. He has more than 20 years of experience from several executive positions within research and development in the international pharmaceutical industry, including Baxter Bioscience, Nycomed/Takeda, Biovitrum, Bayer Pharmaceuticals and AstraZeneca.

The Nomination Committee recommends the elected board members to build their own holdings of shares in the company

Similar to previous years, the Nomination Committee recommends the Board of Directors of Swedish Orphan Biovitrum AB (publ) to establish a shareholding policy pursuant to which the members of the Board of Directors, who do not already have such holding, are expected to, over a five year period, acquire an ownership in Swedish Orphan Biovitrum AB (publ) shares with a market value which is expected to correspond to at least one year board remuneration, before taxes, excluding remuneration for committee work.